Trending: Roche to Buy Telavant From Roivant and Pfizer
1504 ET -- Roche Holding and Pfizer are among the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Roche agreed to buy Telavant Holdings from Roivant Sciences and Pfizer, a deal that includes $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is developing a bowel-disease treatment. On Friday, Pfizer said the Food and Drug Administration approved Penbraya, a vaccine for meningococcal disease. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
October 23, 2023 15:26 ET (19:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing